Prescribing information

 

In this webinar, Dr Patricia Campbell, Consultant Cardiologist at the Southern Health and Social Care Trust, leads a conversation into what optimal treatment for chronic HFrEF looks like in 2021. Dr Katherine McCreary, Senior Heart Failure and Devices Fellow at the Jubilee Hospital Glasgow, then discusses why Entresto should be considered as a first choice treatment for eligible chronic HFrEF patients. She shares real-world experience and the evidence behind this approach. Mandie Welch, Lead Heart Failure Advanced Nurse Practitioner within Cwm Taf Morgannwg University Health Board, presents the recent guidance change in Wales, along with the innovative app-based approach being trialled to efficiently manage patient treatment.

 

Indication: Entresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.1

HFrEF, heart failure with reduced ejection fraction.

Reference

  1. Entresto Summary of Product Characteristics, 2021.
Rate this content: 
No votes yet
UK | August 2021 | 145646
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]